Hidradenitis suppurativa (HS), systemic inflammatory response syndrome and sepsis, sepsis caused by HS: an empty systematic review.
2024The British journal of dermatology
Maghari I, Abiad H, Griffin T, Albrecht J
PubMedHOMER ABIAD, M.D.
OAK FOREST, IL
Internal Medicine - Infectious Disease NPI registered 21+ years 4 publications 2001 – 2024 NPI: 1871596817
What does HOMER ABIAD research?
Dr. Homer Abiad studies how to improve medical care in long-term care facilities, especially regarding the use of antibiotics. He has developed educational programs that help doctors use antibiotics more effectively, ensuring that patients receive the right treatments. Additionally, he investigates the impacts of hepatitis D virus infections in individuals with developmental disabilities, highlighting the increased risks these patients face regarding liver disease and related health problems.
Key findings
- Following an educational intervention, appropriate antibiotic use in long-term care facilities increased significantly from 38% to 62%.
- The rate of initial antibiotic treatments aligning with guidelines improved from 11% to 39%.
- The duration of antibiotic use decreased by nearly 30%, and the initiation of new antibiotic treatments was reduced by about 26%.
- In patients with hepatitis B co-infected with hepatitis D, the risk of dying from liver disease was 11%, compared to only 0.6% for those without hepatitis D.
- Individuals with hepatitis D were more likely to develop serious liver conditions, such as cirrhosis, at rates of 21% compared to 9% for those without hepatitis D.
Frequently asked questions
- Does Dr. Abiad study antibiotic use?
- Yes, Dr. Abiad focuses on improving antibiotic use in long-term care facilities through educational interventions.
- What diseases does Dr. Abiad research?
- He studies the impacts of hepatitis D virus infections, particularly in patients with developmental disabilities.
- Is Dr. Abiad's work relevant to patients with liver disease?
- Absolutely, his research highlights the increased risks of liver disease in patients with hepatitis D.
- What improvements in antibiotic prescribing has Dr. Abiad achieved?
- His intervention led to a significant increase in appropriate antibiotic prescribing and a decrease in unnecessary antibiotic days.
- How does Dr. Abiad's work affect long-term care patients?
- His work helps ensure that long-term care patients receive safer and more effective antibiotic treatments.
Publications in plain English
An educational intervention to improve antimicrobial use in a hospital-based long-term care facility.
2007Journal of the American Geriatrics Society
Schwartz DN, Abiad H, DeMarais PL, Armeanu E, Trick WE +2 more
Plain English
This study focused on improving how antibiotics are used in long-term care facilities by educating doctors and implementing guidelines. After training, the rate of appropriate antibiotic use increased significantly—62% of patients showed symptoms that met guidelines for diagnosis compared to 38% before the intervention, and initial treatments aligned with guidelines rose from 11% to 39%. Overall, the number of days patients received antibiotics dropped by nearly 30%, and the start of new antibiotic treatments decreased by about 26%, demonstrating a lasting improvement in care.
Who this helps: This benefits patients in long-term care facilities, ensuring they receive safer and more effective treatments.
Does the use of fluoroquinolones for the empiric treatment of pneumonia delay initiation of treatment of tuberculosis?
2002Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Abiad H
PubMedThe natural history of hepatitis D virus infection in Illinois state facilities for the developmentally disabled.
2001The American journal of gastroenterology
Abiad H, Ramani R, Currie JB, Hershow RC
Plain English
This study examined the effects of hepatitis D virus infection in people with developmental disabilities living in state facilities in Illinois. Researchers analyzed data from 231 individuals carrying hepatitis B, finding that 65 were also infected with hepatitis D. They discovered that those with hepatitis D had a much higher risk of dying from liver disease (11% compared to 0.6% for those without hepatitis D) and were more likely to develop serious liver conditions like cirrhosis (21% vs. 9%).
Who this helps: This research benefits patients with hepatitis B and D, as well as the healthcare providers caring for them.
Frequent Co-Authors
Ibrahim Maghari Tina Griffin Joerg Albrecht David N Schwartz Patricia L DeMarais Emilian Armeanu William E Trick Yue Wang Robert A Weinstein R Ramani
Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.